
CLAIMS

1. A compound of formula (I) or a salt, solvate or prodrug thereof:



(I)

wherein R_1 and R_2 are independently selected from optionally substituted alkyl, optionally substituted alkenyl or optionally substituted alkynyl;

X is selected from optionally substituted cycloalkylene, optionally substituted heterocyclylene, optionally substituted arylene or optionally substituted heteroarylene;

Y is optionally substituted cycloalkylene; and

Z is selected from optionally substituted -N-heterocyclyl, optionally substituted –NH(heterocyclyl), optionally substituted -NH(cycloalkyl), optionally substituted -NH(aryl) or optionally substituted -NH(heteroaryl);

wherein at least one of X, Y or Z is an optionally substituted bridged moiety.

2. The compound of formula (I) according to claim 1, or a salt, solvate or prodrug thereof:

wherein R_1 and R_2 are independently selected from optionally substituted alkyl, optionally substituted alkenyl or optionally substituted alkynyl;

X is selected from optionally substituted cycloalkylene or optionally substituted arylene;

Y is optionally substituted cycloalkylene; and

Z is selected from optionally substituted -N-heterocyclyl, optionally substituted –NH(heterocyclyl) or optionally substituted -NH(cycloalkyl).

3. The compound according to claims 1 or 2, wherein R_1 and R_2 are independently optionally substituted C_1-C_5 alkyl.

4. The compound according to any of claims 1 to 3, wherein X is optionally substituted bridged cycloalkylene or optionally substituted arylene.

5. The compound according to any of claims 1 to 4, wherein X is optionally substituted bridged bicycloalkylene or optionally substituted arylene.

6. The compound according to any of claims 1 to 5, wherein X is optionally substituted cycloalkylene or optionally substituted arylene, wherein the cycloalkylene or arylene is selected from the following:



.

7. The compound according to any of claims 1 to 6, wherein Y is optionally substituted cycloalkylene, wherein the cycloalkylene is selected from the following:




.

8. The compound according to any of claims 1 to 7, wherein Z is optionally substituted bridged -N-heterocyclyl, or optionally substituted -NH(bridged cycloalkyl).


9. The compound according to any of claims 1 to 8, wherein Z is optionally substituted bridged bicyclic -N-heterocyclyl, or optionally substituted -NH(bridged bicycloalkyl).

10. The compound according to any of claims 1 to 9, wherein Z is selected from the following:




.


11. A compound according to any one of claims 1 to 10, selected from the following:




1




2




3




4




5




6




7




8




9




10




11




12




13




14




15




16




17




18




19




20




21




22




23




24




25




26




27




28




29




30




31




32




33



34



35



36

.

12. A pharmaceutical composition comprising an effective amount of a compound of formula (I) according to any one of claims 1 to 11, or a pharmaceutically acceptable salt, solvate or prodrug thereof.


13. A compound of formula (I) according to any one of claims 1 to 11, or a pharmaceutically acceptable salt, solvate or prodrug thereof for use in treating cancer.

14. Use of a compound of formula (I) according to any one of claims 1 to 11, or a pharmaceutically acceptable salt, solvate or prodrug thereof
in the manufacture of a medicament for treating cancer.

15. The compound for use or use according to claim 13 or 14, wherein the cancer is selected from hepatocellular carcinoma, thyroid cancer, kidney cancer, colorectal cancer, gastrointestinal cancer, skin cancer, lung cancer, and bladder cancer.

16. The compound for use or use according to any one of claims 13 to 15, wherein the cancer is selected from medullary thyroid cancer, gastrointestinal stromal tumor, urothelial carcinoma, metastatic melanoma, renal cell carcinoma, squamous non-small cell lung cancer, small cell lung cancer, and melanoma.

17. A method of synthesizing a compound of formula (I) or a pharmaceutically acceptable salt, solvate or prodrug thereof:



(I)

herein

R_1 and R_2 are independently selected from optionally substituted alkyl, optionally substituted alkenyl, and optionally substituted alkynyl;

X is selected from optionally substituted cycloalkylene, optionally substituted heterocyclylene, optionally substituted arylene, and optionally substituted heteroarylene;


Y is optionally substituted cycloalkylene; and

Z is selected from optionally substituted -N-heterocyclyl, optionally substituted –NH(heterocyclyl), optionally substituted -NH(cycloalkyl), optionally substituted -NH(aryl), and optionally substituted -NH(heteroaryl);

wherein at least one of X, Y or Z is an optionally substituted bridged moiety;

the method comprising:

a) coupling a compound of formula (III)




(III)

with an amine ZH to form the compound of formula (I).

18. The method according to claim 17, wherein the amine ZH is an amine salt and the coupling step is performed in the presence of an amide coupling reagent.

19. The method according to claim 17 or 18, further comprising a step prior to step (a) of:

ia) hydrolyzing a compound of formula (IV)




(IV)

with a base to form a compound of formula (III).


20. The method according to any one of claims 17 to 19, further comprising a step prior to step (ia) of:

iia) coupling a compound of formula (V)



(V)

with a compound of formula (VI)



(VI)

to form a compound of formula (IV).